Tilray Brands TLRY

Chemicals, Basic Materials

$2.81

−4.10%

Market cap: $415.3M
PE: n/m; a loss over the last year
Forward PE: n/m; not a meaningful number
Price to sales: 0.4×
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: $963.1M; +16% on a year ago
Net margin: −17.1%
Free cash flow yield: n/m; not a meaningful number

Tilray Brands trades at 0.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $963.1M over the last twelve months, up 16% on a year earlier with a −17% net margin.

Charts

Financials

Income statement for TLRY, by quarter
Income statement	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
	$193.8M+34%	$188.3M+29%	$229.9M+25%	$200M+13%	$210.9M+9%	$185.8M−1%	$224.5M−2%	$209.5M+5%	$217.5M+3%	$206.7M+11%	$281.7M+26%	$257.1M+23%
Cost of revenue	$146.4M+45%	$138.9M−12%	$147.5M+26%	$140.3M+6%	$149.7M+2%	$133.8M−4%	$156.9M+6%	$152M+8%	$160M+7%	$151.8M+14%	$191.2M+22%	$179.6M+18%
Gross profit	$47.4M+11%	$49.4M	$82.3M+23%	$59.7M+35%	$61.2M+29%	$52M+5%	$67.6M−18%	$57.5M−4%	$57.5M−6%	$55M+6%	$90.5M+34%	$77.5M+35%
R&D	$56K−66%	$106K−38%	$394K+119%	$105K+33%	$60K+7%	$85K−20%	$34K−91%	$41K−61%	$78K+30%	$62K−27%	$180K+429%	$89K+117%
SG&A	$50.9M+7%	$49.9M+10%	$56.4M−1%	$55.8M+18%	$62.2M+22%	$53.2M+6%	$52.3M−7%	$54M−3%	$63M+1%	$60.8M+15%	$75.2M+44%	$71.2M+32%
	−$41.8M−19%	−$82.1M−93%	−$16.5M−82%	−$36.6M+6%	−$42.2M+1%	−$759.9M+826%	−$1.4B+8638%	$2.1M	−$22.3M−47%	−$26.4M−97%	−$16.5M−99%	−$24.1M
Interest expense	$8.6M+178%	$8.5M+719%	$22.3M−41%	$9.8M+0%	$7.8M−10%	$8.4M−2%	$15.3M−31%	$6.7M−32%	$5.4M−31%	$5M−41%	$12.9M−16%	$6.5M−3%
Pre-tax income	−$49.6M−32%	−$107.9M−91%	−$43M−62%	−$33.8M−31%	−$83.2M+68%	−$792.3M+635%	−$1.4B+3139%	−$772K−98%	−$40M−52%	−$23.3M−97%	−$24.1M−98%	−$38.3M+4862%
	−$3.4M	−$2.9M−73%	−$27.6M	$886K−88%	$2M	$1.2M	−$125.1M+353%	−$2.3M	$3.5M+74%	$2M+64%	$13.9M	$1.7M
Net income	−$49M−29%	−$92.7M−92%	−$31.7M−77%	−$39.2M−45%	−$85.3M+74%	−$789.4M+752%	−$1.3B+3909%	−$322K−99%	−$44.9M−47%	−$26.6M−97%	−$49.6M−96%	−$43.1M+13298%
	−$0.70−36%	−$1.20−94%	−$0.40−80%	−$0.40−60%	−$0.99+41%	−$8.69+624%	−$13.01+3153%	$0.00	−$0.41−59%	−$0.24−97%	−$0.42−97%	−$0.32
	73.1M+20%	75.4M+23%	79.4M+17%	87.5M+27%	86.5M+18%	90.8M+20%	97.8M+23%	106M+21%	110.3M+28%	112.7M+24%	118.3M+21%	133.3M+26%

Revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY18: 6 months less the 3 months printed beside them.

R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

SG&A: Q1 FY17: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Net income: Q1 FY18: 6 months less the 3 months printed beside them.

EPS, diluted: 11 periods, Q1 FY17 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY17 and Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY17 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Chemicals nearest Tilray Brands' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
TLRYTilray Brands	$415.3M	n/m	n/a	0.4×	+16%	−17.1%
FTKFlotek Industries	$865.7M	24.1×	27.6×	3.0×	+37%	13.0%
NAGENiagen Bioscience	$192.3M	13.5×	27.0×	1.5×	+11%	12.4%
CRONCronos	$1.2B	16.8×	25.0×	6.9×	+37%	39.1%
FTLFFitlife Brands	$78.4M	13.5×	15.3×	0.8×	+61%	6.2%
ROGRogers	$2.2B	71.4×	34.3×	2.7×	+5%	3.7%
NGVTIngevity	$2.4B	47.4×	19.9×	2.1×	−4%	4.7%
IOSPInnospec	$2.4B	20.1×	22.3×	1.3×	+3%	6.6%
FULFuller H B	$2.7B	13.8×	22.9×	0.8×	+1%	5.6%
WDFCWD 40	$2.9B	32.3×	39.2×	4.2×	+10%	13.2%
AVNTAvient	$3.8B	22.2×	20.2×	1.1×	+2%	5.1%
Peer median	$2.3B	21.2×	23.9×	1.8×	+8%	6.4%